Palatin Technologies believes its existing cash and cash equivalents, along with expected other receivables, will be sufficient to fund operations through June 30, 2027, supporting ongoing development plans.
Bullish
Palatin Technologies achieved $3.9M in collaboration and license revenue and reduced its net loss to $1.4M, while advancing key MC4R agonist programs towards IND submissions in 2026 and 2027.
Bearish
Palatin Technologies' operating expenses increased to $5.5M, and existing cash is projected to fund operations only through June 30, 2027, highlighting a limited cash runway amidst significant unmet medical needs in target disorders.